Advancing Muscle-Invasive Urothelial Carcinoma Management

Management of muscle-invasive urothelial carcinoma (MIUC) is entering a new era. For years, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has remained the gold standard. However, many patients cannot undergo this regimen due to renal dysfunction or significant comorbidities. Neoadjuvant immune checkpoint inhibitors (ICIs) are now emerging as a transformative alternative for these individuals. This systematic review evaluates the efficacy and safety of ICIs in the preoperative setting.

The Impact of Neoadjuvant Immune Checkpoint Inhibitors

The meta-analysis demonstrates that neoadjuvant immune checkpoint inhibitors significantly improve clinical outcomes. Specifically, these agents achieve a pathological complete response (pCR) in approximately 31% to 37% of patients. This response rate is highly encouraging, especially for those ineligible for traditional chemotherapy. Furthermore, ICIs show a favorable safety profile compared to molecular targeted agents. Grade 3 or higher adverse events occur in roughly 35% of cases. Consequently, surgeons can proceed with radical cystectomy without significant delays. Notably, high PD-L1 expression often correlates with better response rates. Therefore, clinicians might use biomarkers to select the best candidates for this therapy in the future.

Moreover, trials like PURE-01 and ABACUS have paved the way for these findings. These studies show that pembrolizumab and atezolizumab can downstage tumors effectively. Additionally, the meta-analysis confirms that ICI monotherapy performs better than targeted agents in terms of pCR and downstaging. Doctors must consider these findings when planning surgery for MIUC patients. This approach not only targets the primary tumor but also addresses potential micrometastatic disease.

FAQs

Can neoadjuvant ICIs replace chemotherapy for all MIUC patients?

Currently, clinical guidelines primarily recommend neoadjuvant immune checkpoint inhibitors for patients who are ineligible for cisplatin. Cisplatin-based chemotherapy remains the standard for fit patients, although ongoing trials are exploring combination therapies.

What is the typical pathological complete response (pCR) rate for ICIs?

Recent meta-analyses indicate that ICI monotherapy achieves a pCR rate between 31% and 37%. When oncology teams combine these with chemotherapy, these rates may increase significantly.

Are there significant risks of delaying surgery when using neoadjuvant ICIs?

Evidence suggests that most patients tolerate ICIs well enough to undergo radical cystectomy on schedule. Serious adverse events occur in about 35% of patients, but surgical delays remain relatively rare.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Menegat ALRS et al. Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis. Immunotherapy. 2026 Mar 12. doi: 10.1080/1750743X.2026.2643128. PMID: 41816870.


2. Yajima S, et al. Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta-analysis. BJUI Compass. 2025 May 26;6(5):e70031. doi: 10.1002/bco2.70031.


3. Necchi A, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01). J Clin Oncol. 2018 Dec 1;36(34):3353-3360. doi: 10.1200/JCO.18.01148.